Pill Burden: A Major Barrier to HAART Adherence and Fixed Dose Combinations (FDCS) as its Solution - A Mini-Review.

IF 0.8 4区医学 Q4 IMMUNOLOGY

Current HIV Research Pub Date : 2024-01-01 DOI:10.2174/011570162X307740240604115154

Mugisa Simon, Ssebaduka Derrick, Sreya Kosanam, Rajeshwari Pasupula

{"title":"Pill Burden: A Major Barrier to HAART Adherence and Fixed Dose Combinations (FDCS) as its Solution - A Mini-Review.","authors":"Mugisa Simon, Ssebaduka Derrick, Sreya Kosanam, Rajeshwari Pasupula","doi":"10.2174/011570162X307740240604115154","DOIUrl":null,"url":null,"abstract":"<p><p>HIV/ AIDS is a global pandemic, one of the most challenging; with no cure for the disease, various therapies available in the form of regimens as Highly Active Anti-Retroviral Therapy (HAART) or simply Anti-Retroviral Therapy (ART) are the only way to manage the disease. The Fixed Dose Combinations (FDCs) concept has been a well-recognised improvement in pharmacotherapy for the treatment of a variety of chronic maladies like hypertension, diabetes, HIV/AIDS, and several FDC products consisting of HIV drugs are approved. These single-tablet regimens have been essential in streamlining ART, lowering pill burden and increasing adherence. Adherence to HAART is the most vital factor to ensure medication success and virologic suppression. However, adherence is faced with several barriers including adverse effects of drugs, the complexity of ART, social-cultural factors, and pill burden among others. This writing reviews the concept of adherence to ART, and its barriers while stressing pill burden as a significant one which we suggest would be solved by using Fixed Dose Combinations (FDCs).</p>","PeriodicalId":10911,"journal":{"name":"Current HIV Research","volume":" ","pages":"143-152"},"PeriodicalIF":0.8000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current HIV Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/011570162X307740240604115154","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

HIV/ AIDS is a global pandemic, one of the most challenging; with no cure for the disease, various therapies available in the form of regimens as Highly Active Anti-Retroviral Therapy (HAART) or simply Anti-Retroviral Therapy (ART) are the only way to manage the disease. The Fixed Dose Combinations (FDCs) concept has been a well-recognised improvement in pharmacotherapy for the treatment of a variety of chronic maladies like hypertension, diabetes, HIV/AIDS, and several FDC products consisting of HIV drugs are approved. These single-tablet regimens have been essential in streamlining ART, lowering pill burden and increasing adherence. Adherence to HAART is the most vital factor to ensure medication success and virologic suppression. However, adherence is faced with several barriers including adverse effects of drugs, the complexity of ART, social-cultural factors, and pill burden among others. This writing reviews the concept of adherence to ART, and its barriers while stressing pill burden as a significant one which we suggest would be solved by using Fixed Dose Combinations (FDCs).

Abstract Image

查看原文本刊更多论文

药片负担：药片负担：坚持接受 HAART 治疗的主要障碍和固定剂量复合制剂 (FDCS) 作为其解决方案--微型综述。

艾滋病毒/艾滋病是一种全球性流行病，也是最具挑战性的疾病之一；由于无法治愈这种疾病，以高活性抗逆转录病毒疗法（HAART）为形式的各种疗法是控制疾病的唯一方法。坚持 HAART 是确保药物治疗成功和病毒抑制的最关键因素。然而，坚持治疗面临着多种障碍，包括抗逆转录病毒疗法（ART）药物的不良反应、抗逆转录病毒疗法的复杂性、社会和文化因素以及服药负担等。固定剂量复方制剂（FDC）的概念已被公认为是药物疗法的一种改进，可用于治疗高血压、糖尿病、艾滋病等多种慢性疾病，目前已有几种由艾滋病药物组成的固定剂量复方制剂产品获得批准。本文回顾了坚持抗逆转录病毒疗法的概念及其障碍，同时强调药片负担是一个重要问题，我们建议使用固定剂量复方制剂（FDC）来解决这一问题。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current HIV Research 医学-病毒学

CiteScore

1.90

自引率

10.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Current HIV Research covers all the latest and outstanding developments of HIV research by publishing original research, review articles and guest edited thematic issues. The novel pioneering work in the basic and clinical fields on all areas of HIV research covers: virus replication and gene expression, HIV assembly, virus-cell interaction, viral pathogenesis, epidemiology and transmission, anti-retroviral therapy and adherence, drug discovery, the latest developments in HIV/AIDS vaccines and animal models, mechanisms and interactions with AIDS related diseases, social and public health issues related to HIV disease, and prevention of viral infection. Periodically, the journal invites guest editors to devote an issue on a particular area of HIV research of great interest that increases our understanding of the virus and its complex interaction with the host.